Recently, several meta-analyses analyzed different first-line treatments for ES-SCLC patients and demonstrated that PD-L1 inhibitors durvalumab and atezolizumab plus etoposide-based chemotherapy may be the best choice as first-line therapy for ES-SCLC patients (9–11). The gene discussed is CD274; the disease is small cell lung carcinoma.